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Abstract: The association of specific urinary proteins other than albumin with cardiovascular (CV)
outcomes in patients with type 2 diabetes (T2D) has been shown. In this respect, CV outcomes may
differ in non-albuminuric T2D patients who were considered as a low risk group, according to the
presence of proteinuria. We investigated the association between proteinuria and atherosclerosis
assessed by carotid artery intima-media thickness (CIMT) in non-albuminuric T2D patients. 2047 T2D
patients whose urine albumin-to-creatinine ratio was below 30 mg/g were recruited and classified
into a non-proteinuria (NP, uPCR < 150 mg/g, n = 1865) group and a non-albuminuric proteinuria
(NAP, uPCR ≥ 150 mg/g, n = 182) group. CIMT was compared between the two groups and logistic
regression analysis was conducted to verify whether proteinuria could predict deteriorated CIMT
status. In this cross-sectional study, mean CIMT of the NAP group were significantly thicker than
those of the NP group (0.73 ± 0.16 vs. 0.70 ± 0.14, p = 0.016). The presence of proteinuria is
associated with deteriorated CIMT after the adjustment for conventional risk factors (odds ratio,
2.342; 95% confidence interval, 1.082–5.070, p = 0.030) in regression analysis. We postulated that
the measurement of urinary protein in conjunction with albumin might be helpful for predicting
atherosclerosis, especially for non-albuminuric patients.
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1. Introduction
Cardiovascular disease (CVD), the main pathological consequence of atherosclerosis, is a major
factor of morbidity and mortality in patients with type 2 diabetes (T2D) [1,2]. Therefore, the early
detection of atherosclerosis to screen for CVD in T2D patients is urgently needed. Several surrogate
markers for subclinical atherosclerosis have been introduced, such as carotid artery intima-media
thickness (CIMT), ankle-brachial index (ABI), and pulse wave velocity (PWV) [3–5].
CIMT measured by carotid ultrasonography is one of the most frequently performed tests for
screening T2D patients for atherosclerosis. Because of a lack of a uniform methodology, it remains
controversial whether CIMT could be a consistent screening tool for atherosclerosis. However, CIMT is
a clinically important screening tool for atherosclerosis because it is convenient to perform and there is
abundant evidence of its association with CVD or vascular complications of T2D [6–9].
Along with the estimated glomerular filtration rate (eGFR), the quantification of urinary albumin
is generally recommended to screen for diabetic kidney disease (DKD) in T2D patients [10]. Increased
albuminuria is defined as ≥30 mg/g creatinine, and this abnormal condition has been reported to be
associated with CVD and mortality [11–14] as well as glomerular damage [15]. However, it is well
known that DKD may progress without increases in albuminuria [16,17].
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In this context, several tubular damage markers such as fatty acid-binding proteins (FABPs) and
N-acetyl-β-d-glucosaminidase (NAG) have gained attention for their correlations with DKD [18,19].
These markers, specific urinary proteins other than albumin, are also associated with other diabetic
complications and CVD [20–26]. These previous studies suggest that even in non-albuminuric T2D
patients, there was a significant difference in the risk or status of vascular complications depending on
the presence of proteinuria. Therefore, in this study, we recruited T2D patients without albuminuria
and evaluated the association between total proteinuria and atherosclerosis assessed by CIMT.
2. Materials and Methods
2.1. Study Population
This retrospective cross-sectional observational study included patients who visited the diabetes
centre at Severance Hospital in Seoul, South Korea, between July 2015 and July 2018. A total of
2047 non-albuminuric patients with T2D who simultaneously underwent laboratory measurements
and carotid ultrasonography were recruited. A non-albuminuric patient was defined as having a
urine albumin-to-creatinine ratio (ACR) of <30 mg/g. T2D was defined as: (1) use of insulin or
antihyperglycemic agents (AHAs) or (2) a glycated haemoglobin (HbA1c) level ≥ 6.5%. Patients were
excluded if they fulfilled any one of the following criteria: (1) <19 years of age; (2) current pregnancy;
(3) end stage renal disease (defined as eGFR < 15 mL/min/1.73 m2); and (4) presence of significantly
elevated transaminases (aspartate aminotransferase or alanine aminotransferase ≥5 times the upper
limit of normal).
Demographic data such as age, sex, blood pressure, and body mass index (BMI) were retrospectively
collected from the patients’ electronic medical records. BMI was calculated as weight divided by
height squared (kg/m2). We collected records of the medications related to atherosclerosis such
as anti-platelet agents and lipid-lowering agents by searching the electronic medical records. We
also identified medical history of hypertension (HTN) by antihypertensive medication usage and
International Classification of Disease 10th revision (ICD-10) diagnosis codes as followed; I10.0, I10.1,
I10.9. Finally, to assess the vascular condition of subjects, we reviewed ICD-10 codes of cardiovascular
diseases (CVDs) as followed; I20.x, I21.x, I22.x, I24.x, I25.x, I60.x, I61.x, I63.x–I69.x, G45.x (not G45.4).
The study protocol received ethical approval from the institutional review board at the Yonsei
University College of Medicine (No. 4-2019-0107), which waived the need for informed consent because
the database was only retrospectively accessed for analytical purposes and personal information was
not used.
2.2. Measurements of Clinical and Laboratory Parameters
Following an overnight fast (≥8 h), blood samples were obtained to measure glucose, HbA1c, lipid
profile, blood urea nitrogen (BUN), creatinine, and liver enzymes. Low-density lipoprotein cholesterol
(LDL-C) was calculated using the Friedewald equation if there was no actual LDL-C measurement [27].
If a patient’s triglyceride (TG) level exceeded 400 mg/dL, we did not use the equation. Spot urine tests
for proteinuria, including protein, albumin, and creatinine, were performed using an AU680 analyzer
(Beckman Coulter Inc., Brea, CA, USA). Calculated urine ACR was used as inclusion or exclusion
criteria. Proteinuria was defined as urine protein-to-creatinine ratio (PCR) ≥ 150 mg/g [28]. The eGFR
was calculated using the Modification of Diet in Renal Disease study equation [29].
2.3. Measurements of CIMT
Two specialized technicians conducted common carotid arterial ultrasound examinations using
an Aplio 500 instrument (Toshiba, Tokyo, Japan) equipped with a 13-MHz linear probe using CIMT
measurement protocols described in detail previously [30]. In brief, CIMT were recorded with the
subject in a supine position with the head elevated to 45◦ and tilted to either side by 30◦. We performed
B mode examinations about 1.5 cm proximal to the carotid bifurcation on the far wall of the common
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carotid artery and on both sides. IMT was defined as the distance between the media–adventitia
interface and the lumen–intima interface. Mean CIMT was defined as the mean IMT of the right and
left carotid arteries. Mean of maximum CIMT was defined as the mean maximum IMT of the right
and left carotid arteries. Carotid plaques were determined according to Mannheim consensus [31].
The presence of carotid plaques was positive when one or more carotid plaques existed. Considering
previous studies and recommendations, we defined an abnormal (or significantly increased) CIMT as
an absolute mean IMT value of ≥ 1 mm [6,32].
2.4. Statistical Analysis
The baseline characteristics, laboratory measurements, and CIMT were compared according to
proteinuria status. Student’s t-test and the X2 test were used to compare continuous and categorical
variables between the two groups. Correlations between proteinuria, CIMT, and other independent
variables were analysed with Spearman’s correlation coefficients.
Multiple logistic regression analyses were performed to evaluate whether proteinuria could
predict an abnormal CIMT. First, we conducted the unadjusted logistic regression analysis. And then,
we made three multiple logistic regression models adjusted by various factors which could affect CIMT,
such as age, sex, history of CVD and blood cholesterol level. The logistic regression analysis results are
presented as odds ratio (OR) and 95% confidence interval (CI). To assess the predictive accuracy of
proteinuria adjusted by multiple variables, we derived receiver operating characteristics curves of the
logistic regression models for abnormal CIMT and calculated areas under the curve (AUC).
All statistical analyses were performed using SPSS version 21.0 for Windows (IBM Corp.,
Armonk, NY, USA). Continuous variables are expressed as mean ± standard deviation (SD), while
categorical variables are shown as number and percentage (%). p Values < 0.05 were considered
statistically significant.
3. Results
3.1. Study Population Characteristics
Of the 2047 non-albuminuric T2D patients, 1865 were non-proteinuric (NP) and the remaining 182
had proteinuria (non-albuminuric proteinuria [NAP]) (Table 1). The mean urine PCR was 87.6 mg/g in
the NP group and 205.6 mg/g in the NAP group.
Patients in the NAP group tended to be leaner (mean BMI, 24.4 ± 3.3 vs. 25.5 ± 3.5, p = 0.002) and
older (64.4 ± 9.6 vs. 59.7 ± 10.7, p < 0.001). NAP patients also showed lower diastolic blood pressure
(71.6 ± 10.7 vs. 74.2 ± 10.3, p = 0.009). The percentage of patients with CVDs was higher (47.3% vs.
39.7%, p = 0.047), and drinking history was lower (12 of 49 vs 297 of 581 patients who had related
records, p < 0.001) in NAP group. Serum glucose and HbA1c were significantly higher in the NAP
group (142.8 ± 47.6 vs. 133.3 ± 38.3, p = 0.009; 7.6 ± 1.6 vs. 7.1 ± 1.2, p < 0.001). Blood lipid profiles
were generally lower in NAP; total cholesterol (154.5 ± 32.3 vs. 159.8 ± 33.7, p = 0.043), high-density
lipoprotein cholesterol (HDL-C, 46.0 ± 11.9 vs. 47.8 ± 11.2, p = 0.038), and LDL-C (80.2 ± 29.5 vs. 86.3
± 30.1, p = 0.009) were higher in the NP group.
BUN levels of the NAP patients were higher than those of the NP group (17.2 ± 5.6 vs. 15.6 ±
4.6, p < 0.001), but there was no significant intergroup difference in renal function (eGFR, 89.7 ± 27.7
vs. 93.3 ± 22.6, p = 0.093) and no significant intergroup differences in liver enzymes or history of
antiplatelet or lipid lowering agent usage.
Mean CIMT and mean of maximum CIMT were significantly increased in the NAP group (0.73 ±
0.16 vs. 0.70 ± 0.14, p = 0.016; 0.86 ± 0.21 vs. 0.82 ± 0.17, p = 0.008). Patients in the NAP group also
tended to have carotid plaques (136 of 182 (74.7%) vs. 1259 of 1865 (67.5%), p = 0.046).
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Table 1. Participants’ demographic and laboratory characteristics.
Characteristic (unit) NP(n = 1865)
NAP
(n = 182) p Value
Age (years) 59.7 ± 10.7 64.4 ± 9.6 <0.001
Male, n (%) 1049 (56.2%) 98 (53.8%) 0.533
BMI (kg/m2) 25.5 ± 3.5 24.4 ± 3.3 0.002
Systolic blood pressure (mmHg) 123.8 ± 12.0 122.3 ± 13.8 0.189
Diastolic blood pressure (mmHg) 74.2 ± 10.3 71.6 ± 10.7 0.009
History of HTN, n (%) 952 (51.0%) 100 (54.9%) 0.369
History of CVD, n (%) 740 (39.7%) 86 (47.3%) 0.047
Coronary heart disease, n (%) 333 (17.9%) 41 (22.5%) 0.119
Other cerebrovascular disease, n (%) 554 (29.7%) 63 (34.6%) 0.168
Smoking history (non/ex-/current), n * 317/159/122 35/8/8 0.090
Drinking history (no/yes), n * 284/297 37/12 <0.001
HbA1c (%) 7.1 ± 1.2 7.6 ± 1.6 <0.001
Fasting glucose (mg/dL) 133.3 ± 38.3 142.8 ± 47.6 0.009
AST (IU/L) 23.6 ± 11.5 23.8 ± 16.6 0.882
ALT (IU/L) 25.2 ± 16.1 25.9 ± 21.9 0.649
Total bilirubin (mg/dL) 0.8 ± 0.3 0.7 ± 0.4 0.044
BUN (mg/dL) 15.6 ± 4.6 17.2 ± 5.6 <0.001
Creatinine (mg/dL) 0.8 ± 0.2 0.8 ± 0.3 0.065
eGFR (MDRD, mL/min/1.73 m2) 93.3 ± 22.6 89.7 ± 27.7 0.093
Total cholesterol (mg/dL) 159.8 ± 33.7 154.5 ± 32.3 0.043
Triglyceride (mg/dL) 130.1 ± 64.2 137.1 ± 72.7 0.165
HDL-C (mg/dL) 47.8 ± 11.2 46.0 ± 11.9 0.038
LDL-C (mg/dL) 86.3 ± 30.1 80.2 ± 29.5 0.009
Urine PCR (mg/g creatinine) 87.6 ± 25.5 205.6 ± 72.5 <0.001
Mean CIMT (mm) 0.70 ± 0.14 0.73 ± 0.16 0.016
Mean of maximum CIMT (mm) 0.82 ± 0.17 0.86 ± 0.21 0.008
Presence of carotid plaques, n (%) 1259 (67.5%) 136 (74.7%) 0.046
Usage of antiplatelet agent, n (%) 672 (36.0%) 75 (41.2%) 0.166
Usage of lipid lowering agent, n (%) 940 (50.4%) 88 (48.4%) 0.597
Continuous variables are expressed as mean ± standard deviation (SD). * Due to relatively small number of evaluable
patient, only number of subjects were presented, without percentage of each group. NP, non-proteinuric group;
NAP, non-albuminuric proteinuria group; BMI, body mass index; HTN, hypertension; CVD, cardiovascular disease;
HbA1c, glycated haemoglobin; AST, aspartate aminotransferase; ALT, alanine aminotransferase; BUN, blood urea
nitrogen; eGFR, estimated glomerular filtration rate; MDRD, Modification of Diet in Renal Disease study equation;
HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; PCR, protein-to-creatinine
ratio; CIMT, carotid artery intima-media thickness.
3.2. Variables Correlated with Significantly Increased CIMT
In Spearman’s correlation analysis, mean CIMT was positively correlated with age, CVD history,
urine PCR, and serum creatinine but negatively correlated with female, diastolic blood pressure, eGFR,
total cholesterol, TG, and HDL-C (Table 2). BMI, smoking or drinking history, and parameters related
to glycaemic control such as fasting glucose and HbA1c were not significantly correlated with CIMT.
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Table 2. Correlations between mean CIMT and other variables.
Characteristic (unit)
All Patients (N = 2047)
r p Value
Age (years) 0.525 <0.001
Sex (Female vs. male) −0.111 <0.001
BMI (kg/m2) −0.027 0.342
Systolic blood pressure (mmHg) 0.024 0.372
Diastolic blood pressure (mmHg) −0.193 <0.001
History of CVD 0.224 <0.001
Smoking history −0.006 0.870
Drinking history 0.047 0.243
Urine PCR (mg/g creatinine) 0.074 <0.001
HbA1c (%) −0.043 0.051
Fasting Glucose (mg/dL) −0.011 0.633
Creatinine (mg/dL) 0.157 <0.001
eGFR (MDRD, mL/min/1.73 m2) −0.149 0.041
Total cholesterol (mg/dL) −0.098 <0.001
Triglyceride (mg/dL) −0.046 0.037
HDL-C (mg/dL) −0.102 <0.001
LDL-C (mg/dL) −0.040 0.067
BMI, body mass index; CVD, cardiovascular disease; PCR, protein-to-creatinine ratio; HbA1c, glycated haemoglobin;
eGFR, estimated glomerular filtration rate; MDRD, Modification of Diet in Renal Disease Study equation;
HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; CIMT, carotid artery
intima-media thickness.
3.3. OR for Significantly Increased CIMT with Proteinuria
We performed multiple logistic regression analyses to investigate the association between the
presence of proteinuria (PCR ≥ 150 mg/g) and a significantly increased mean CIMT (≥1 mm).
In an unadjusted model, the presence of proteinuria was considerably associated with an abnormal
CIMT (OR, 3.8; 95% CI, 1.981–7.289; p < 0.001) (Table 3). When we built a model adjusted for age
and sex (model 1), the presence of proteinuria was still substantially associated with an abnormally
increased CIMT (OR, 2.765; 95% CI, 1.413–5.411; p = 0.003). After further adjustment for HbA1c and
total cholesterol to model 1 (model 2), proteinuria remained statistically significant (OR, 2.395; 95%
CI, 1.206–4.754; p = 0.013). Finally, we additionally adjusted diastolic blood pressure, history of CVD,
eGFR, and lipid lowering agent to model 2 (model 3) and found that the presence of proteinuria was
still significantly associated with abnormal CIMT (OR, 2.881; 95% CI, 1.329–6.244; p = 0.007). Each
model showed meaningful predictive power (AUC of model 1, 0.773; model 2, 0.776, model 3, 0.771;
p value of all models < 0.001) (Figure 1).
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Table 3. Odds ratios for significantly increased CIMT by proteinuria.
Variables OR 95% CI p-Value
Unadjusted
Presence of proteinuria 3.800 1.981–7.289 <0.001
Model 1
Age (years) 1.099 1.062–1.138 <0.001
Sex (female vs. male) 0.584 0.322–1.059 0.077
Presence of proteinuria 2.765 1.413–5.411 0.003
Model 2
Age (years) 1.100 1.063–1.139 <0.001
Sex (female vs. male) 0.608 0.333–1.110 0.105
HbA1c (%) 1.249 1.039–1.501 0.018
Total cholesterol (mg/dL) 0.994 0.985–1.004 0.236
Presence of proteinuria 2.395 1.206–4.754 0.013
Model 3
Age (years) 1.107 1.062–1.153 <0.001
Sex (female vs. male) 0.677 0.333–1.378 0.282
Diastolic blood pressure (mmHg) 0.974 0.942–1.008 0.134
History of CVD 1.056 0.511–2.183 0.882
HbA1c (%) 1.285 0.999–1.653 0.051
eGFR (MDRD, mL/min/1.73 m2) 1.001 0.987–1.015 0.872
Total cholesterol (mg/dL) 0.993 0.981–1.004 0.209
Usage of lipid lowering agent 0.835 0.405–1.721 0.625
Presence of proteinuria 2.881 1.329–6.244 0.007
OR, odds ratio; CI, confidence interval; HbA1c, glycated haemoglobin; eGFR, estimated glomerular filtration rate;
MDRD, Modification of Diet in Renal Disease Study equation; CIMT, carotid artery intima-media thickness.
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4. Discussion
In this study, we found that overt proteinuria is significantly associated with deteriorated CIMT
in non-albuminuric T2D patients. Proteinuria maintained its predictive power for an increased CIMT
in non-albuminuric patients after the adjustment for age, sex, diastolic blood pressure, history of CVD,
HbA1c, eGFR, total cholesterol, and lipid lowering medication. These results indicate that, even in
patients without albuminuria, the risk or status of vascular complications may differ in the presence
of proteinuria.
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Albuminuria and eGFR are the currently established tools for DKD screening in T2D patients [10,33].
Albuminuria, usually defined as≥30 mg/g creatinine, has shown its association with renal outcome [34,35],
cardiovascular disease [13,36], and mortality [11,12]. Albuminuria is also recognized as a more sensitive
marker than eGFR. However, in some cases, DKD progresses without significant albuminuria [16,17]
since it is detected only after glomerular damage occurs. The pathophysiology of DKD is complex;
various pathways and factors, such as the renin-angiotensin-aldosterone system, inflammatory responses,
oxidative stress, and renal hemodynamic changes, are involved in DKD [37]. Therefore, albuminuria, a
marker of glomerular damage, might be insufficient to reflect early-stage DKD, which encompasses a
wide range of mechanisms. In particular, albuminuria is not sensitive to tubular damage, which is also an
important component of early DKD pathology [38,39]. Because the vascular complications of T2D share
pathophysiologic mechanisms, this limitation of albuminuria highlights that vascular complications of
T2D such as CVD may differ, even in patients without albuminuria.
Several urinary proteins that reflect tubular damage, such as FABPs, NAG, neutrophil
gelatinase-associated lipocalin (NGAL), and kidney injury molecule-1 (KIM-1) were introduced
as complimentary markers to albuminuria for DKD. Although there were some conflicting results,
these biomarkers also have shown their associations with CVD; urinary liver-type FABP showed
correlations with the development of end stage renal disease and CVD [40]. The association between
NAG and CVD was reported mainly in diabetic patients [20,22]. In addition, NGAL and KIM-1 have
shown their predictive value for CVD outcomes in various studies [24,25,41]. In particular, KIM-1 was
independently associated with atherosclerotic CVD [23].
However, among the abovementioned biomarkers, no single marker has shown sufficient evidence
or clinical cost-effectiveness to be introduced as a standard screening strategy like albuminuria.
Moreover, assessing multiple biomarkers is inefficient and impractical. Therefore, total proteinuria,
which includes these tubular proteins, is a useful, practical screening tool, especially for non-albuminuric
T2D patients. Assessing total urinary protein or identifying NAP patients would be meaningful in this
context, especially for elderly T2D patients whose progression rate to CKD is usually high [42].
Previous studies have shown that NAP predicts DKD progression [43,44]. Our research team
also reported that patients with NAP were more closely associated with decreased beta cell function
and an increased prevalence of vascular disease [45]. However, few studies have focused on the
relationship between NAP and markers of subclinical atherosclerosis. Moreover, to our knowledge, no
study has evaluated the associations between total proteinuria and atherosclerosis in non-albuminuric
T2D patients. In this study, we recruited non-albuminuric T2D patients and demonstrated that NAP
patients show a higher prevalence of deteriorated atherosclerosis assessed by CIMT than NP patients.
We acknowledge that this study has several limitations. First, owing to its retrospective
cross-sectional study design, we could not make any inference of causality. Second, the numerical
imbalance due to the relatively few patients in the NAP group could be a limitation of the lack of
statistical power. We tried to minimize that limitation by recruiting as large a population as possible
(over 2000 patients). Third, the comparison of CIMT between NAP group and albuminuria group was
not conducted. Therefore, we could not demonstrate CIMT status in the NAP group or the predictive
power of NAP for deteriorated CIMT versus that in albuminuric patients. However, we think that
demonstrating the need for total proteinuria quantification in conjunction with albuminuria to predict
atherosclerosis, especially in non-albuminuric patients, has sufficient clinical significance. Further
studies comparing the NAP and albuminuria groups in terms of carotid artery atherosclerosis (CAA)
are needed. Fourth, because this study included patients who visited the diabetes centre of Severance
Hospital, we could not recruit non-diabetic subjects, so our findings cannot be applied to non-diabetic
patients. Fifth, the list of proteinuria, which would be composed of albumin and various tubular
injury markers, was not examined in this study because we retrospectively used routine laboratory
measurements. Further studies which assess the composition of urinary protein in NAP group are
needed. Sixth, since there were two technicians for CIMT measurement, inter-observer variation may
have occurred. Finally, the cut-off value for abnormal CIMT in this study, 1 mm, may be controversial
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because there is no established single reference value for progressed CIMT. Although the American
Society of Echocardiography Consensus Statement recommended that CIMT ≥ 75th percentile for age,
sex, and ethnicity indicates high risk [32], there is a lack of CIMT percentile data by age and sex for
Koreans. In addition, since this study excluded albuminuric patients, the use of in-group percentile as
a reference point is inappropriate because it could not reflect the absolute high-risk status. Considering
this context, we sought to find the absolute reference value of CIMT and determined the cut-off value
for deteriorated CIMT as 1 mm on the basis of abundant previous studies that proved its clinical
implications or used it as a cut-off point [6,46–49].
5. Conclusions
In this study, we showed that the presence of overt proteinuria is significantly associated with
deteriorated status of CAA in non-albuminuric T2D patients. This result suggests that the measurement
of urinary protein in conjunction with albumin might be helpful for predicting CAA.
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